GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of “Hold” from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received an average recommendation of “Hold” from the nineteen analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.78.

A number of brokerages have recently weighed in on GDRX. UBS Group lifted their target price on shares of GoodRx from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, March 1st. KeyCorp upgraded shares of GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research note on Wednesday, April 10th. Truist Financial upped their target price on shares of GoodRx from $7.50 to $8.00 and gave the stock a “hold” rating in a research note on Friday, March 1st. The Goldman Sachs Group upped their target price on shares of GoodRx from $6.50 to $7.50 and gave the stock a “neutral” rating in a research note on Friday, March 1st. Finally, TD Cowen boosted their price objective on shares of GoodRx from $12.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, March 1st.

GoodRx Stock Down 4.1 %

Shares of NASDAQ:GDRX opened at $6.55 on Tuesday. The firm has a fifty day moving average price of $6.87 and a two-hundred day moving average price of $6.18. The company has a debt-to-equity ratio of 0.85, a current ratio of 7.12 and a quick ratio of 7.12. GoodRx has a one year low of $4.14 and a one year high of $9.37. The company has a market cap of $2.59 billion, a price-to-earnings ratio of -327.34, a PEG ratio of 3.74 and a beta of 1.42.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02. The firm had revenue of $196.64 million for the quarter, compared to analysts’ expectations of $195.59 million. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. Analysts anticipate that GoodRx will post 0.23 EPS for the current fiscal year.

Institutional Investors Weigh In On GoodRx

A number of hedge funds have recently modified their holdings of GDRX. Moneta Group Investment Advisors LLC boosted its stake in GoodRx by 112,694.0% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 17,148,069 shares of the company’s stock worth $79,910,000 after buying an additional 17,132,866 shares during the period. Rubric Capital Management LP acquired a new stake in shares of GoodRx during the fourth quarter worth about $39,348,000. Millennium Management LLC lifted its position in shares of GoodRx by 151.3% during the fourth quarter. Millennium Management LLC now owns 5,318,603 shares of the company’s stock worth $24,785,000 after purchasing an additional 3,202,061 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of GoodRx by 459.0% during the third quarter. Ameriprise Financial Inc. now owns 2,631,227 shares of the company’s stock worth $14,814,000 after purchasing an additional 2,160,541 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. acquired a new stake in shares of GoodRx during the third quarter worth about $8,866,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.